https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-01 / Clin. Cancer Res. 2011 Jul;17(14):4705-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-01 / Clin. Cancer Res. 2011 Jul;17(14):4705-182011-06-01 00:00:002019-02-15 08:46:41Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-01 / Front Biosci (Schol Ed) 2011 Jun;3:1486-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-01 / Front Biosci (Schol Ed) 2011 Jun;3:1486-992011-06-01 00:00:002019-02-15 08:50:08Cancer stem cells: perspectives of new therapeutical approaches for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-24 / Nat Rev Clin Oncol 2011 May;8(9):551-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-24 / Nat Rev Clin Oncol 2011 May;8(9):551-612011-05-24 00:00:002019-02-15 08:53:07Immunotherapy for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-12 / Cell. Immunol. 2011;270(2):188-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-12 / Cell. Immunol. 2011;270(2):188-972011-05-12 00:00:002019-02-15 08:40:05Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-10 / Clin. Cancer Res. 2011 Jul;17(13):4558-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-10 / Clin. Cancer Res. 2011 Jul;17(13):4558-672011-05-10 00:00:002019-02-15 08:52:51Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-06 / Cancer Immunol. Immunother. 2011 Aug;60(8):1097-107
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-06 / Cancer Immunol. Immunother. 2011 Aug;60(8):1097-1072011-05-06 00:00:002019-02-15 08:52:38Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-01 / J. Immunother. 2011 May;34(4):382-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-01 / J. Immunother. 2011 May;34(4):382-92011-05-01 00:00:002019-02-15 08:46:42Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-25 / Clin Med Insights Oncol 2011;5:107-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-25 / Clin Med Insights Oncol 2011;5:107-152011-04-25 00:00:002019-02-15 08:40:05The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-20 / PLoS ONE 2011 Apr;6(4):e18801
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-20 / PLoS ONE 2011 Apr;6(4):e188012011-04-20 00:00:002019-02-15 08:53:13Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-05 / Mol. Ther. 2011 Aug;19(8):1558-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-05 / Mol. Ther. 2011 Aug;19(8):1558-682011-04-05 00:00:002019-02-15 08:40:06Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF
